Topic:
Financials
Latest Headlines
Latest Headlines
Interleukin Genetics raises $12M in last-ditch save
Interleukin Genetics just got a $12 million shot in the arm, a private placement funding that will be crucial to its survival as a developer of genetic tests for chronic conditions.
Sequester cuts threaten FDA's access to industry user fees
According to AdvaMed, the user fees that industry players contribute to the FDA, money that currently helps the agency retain staff and support programs, may now take a hit to the tune of about $2.9 million.
NanoString files for $86M IPO
Fresh off the launch its gene-expression cancer diagnostic, Seattle's NanoString is plotting an IPO worth up to $86.3 million, the company disclosed Monday.
Shire eyes takeover protection as bid rumors swirl, Mail says
Shire ($SHPG) is a perennial entry on everybody's favorite M&A target list. Now, according to the Daily Mail , Shire is putting its ducks in a row for a potential "special dividend" to counter any takeover interest. Word is, an £11 billion hostile bid is coming.
Ex-HGS director draws fire for plugging anthrax drug at Pentagon
According to a Los Angeles Times investigation, former Navy Secretary Richard Danzig talked up HGS' anthrax drug raxibacumab to his government contacts--at a time when he also served on the company's board.
After successful IPO, Quintiles plots 400 job cuts
Global CRO Quintiles is planning to slash 400 jobs this year, the company disclosed in a regulatory filing, primarily from its product development and healthcare services departments.
PRA winds up for IPO
Perhaps encouraged by the success of its North Carolina neighbor Quintiles, PRA is making moves toward an IPO of its own, filing a confidential draft registration form with the SEC.
20 Highest-Paid Biopharma CEOs of 2012
Call it a rite of spring. Every year about this time, FiercePharma takes a look at executive compensation in the industry, and we rank the highest-paid CEOs. If you're a regular reader, you'll notice that this year's list is longer than previous editions. And there's a reason for that: curiosity. Check out the report >>
India sets controversial price caps on 650 drugs
India has started the countdown on new price controls for a vastly expanded list of drugs, a move that is expected to cut deeply into the profits of drugmakers for hundreds of drugs.
Thermedical scores $5.5M in funding for tumor, heart ablation research
Massachusetts-based devicemaker Thermedical secured $5.5 million to hire additional staff and advance research in ablation for solid tumors and ventricular tachycardia, a dangerous arrhythmia of the heart, bringing the company's total first round of financing to $7 million.
